NASDAQ:PCVX
Vaxcyte, Inc.
Vaxcyte, Inc. reported net income of −$766.6M in fiscal 2025. Free cash flow was −$669.3M, and the diluted share count rose 11.6%.Summary generated from Vaxcyte, Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−25.6%
Debt / equityn/a
Free cash flow−$669.3M
FCF marginn/a
Share count change+11.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −104 | −232 | −468 | −570 | −924 |
| Net income | −100 | −223 | −402 | −464 | −767 |
| Free cash flow | −128 | −176 | −313 | −475 | −669 |
Recent filings
- 8-KEntry into a material agreement
Oct 9, 2026 - 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 7, 2026 - 8-KRegulation FD disclosure
Oct 5, 2026 - 8-KDirector or officer change
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KDirector or officer change
Jul 15, 2026